首页> 外文期刊>Veterinary research >Efficient strategy for constructing duck enteritis virus-based live attenuated vaccine against homologous and heterologous H5N1 avian influenza virus and duck enteritis virus infection
【24h】

Efficient strategy for constructing duck enteritis virus-based live attenuated vaccine against homologous and heterologous H5N1 avian influenza virus and duck enteritis virus infection

机译:构建基于鸭肠道炎病毒的减毒活疫苗的有效策略,该疫苗针对同源和异源H5N1禽流感病毒和鸭肠道炎病毒感染

获取原文
           

摘要

Duck is susceptible to many pathogens, such as duck hepatitis virus, duck enteritis virus (DEV), duck tembusu virus, H5N1 highly pathogenic avian influenza virus (HPAIV) in particular. With the significant role of duck in the evolution of H5N1 HPAIV, control and eradication of H5N1 HPAIV in duck through vaccine immunization is considered an effective method in minimizing the threat of a pandemic outbreak. Consequently, a practical strategy to construct a vaccine against these pathogens should be determined. In this study, the DEV was examined as a candidate vaccine vector to deliver the hemagglutinin (HA) gene of H5N1, and its potential as a polyvalent vaccine was evaluated. A modified mini-F vector was inserted into the gB and UL26 gene junction of the attenuated DEV vaccine strain C-KCE genome to generate an infectious bacterial artificial chromosome (BAC) of C-KCE (vBAC-C-KCE). The HA gene of A/duck/Hubei/xn/2007 (H5N1) was inserted into the C-KCE genome via the mating-assisted genetically integrated cloning (MAGIC) to generate the recombinant vector pBAC-C-KCE-HA. A bivalent vaccine C-KCE-HA was developed by eliminating the BAC backbone. Ducks immunized with C-KCE-HA induced both the cross-reactive antibodies and T cell response against H5. Moreover, C-KCE-HA-immunized ducks provided rapid and long-lasting protection against homologous and heterologous HPAIV H5N1 and DEV clinical signs, death, and primary viral replication. In conclusion, our BAC-C-KCE is a promising platform for developing a polyvalent live attenuated vaccine.
机译:鸭子易感染许多病原体,例如鸭子肝炎病毒,鸭子肠炎病毒(DEV),鸭子tembusu病毒,H5N1高致病性禽流感病毒(HPAIV)。由于鸭在H5N1 HPAIV的进化中起着重要作用,因此通过疫苗免疫控制和消除鸭中H5N1 HPAIV被认为是一种有效的方法,可最大程度地减少大流行病爆发的威胁。因此,应该确定构建针对这些病原体的疫苗的实用策略。在这项研究中,将DEV作为传递H5N1血凝素(HA)基因的候选疫苗载体进行了研究,并评估了其作为多价疫苗的潜力。将修饰的mini-F载体插入减毒的DEV疫苗株C-KCE基因组的gB和UL26基因连接处,以产生C-KCE的感染性细菌人工染色体(BAC)(vBAC-C-KCE)。通过交配辅助遗传整合克隆(MAGIC)将A /鸭/湖北/ xn / 2007的HA基因(H5N1)插入C-KCE基因组,以产生重组载体pBAC-C-KCE-HA。通过消除BAC主链开发了二价疫苗C-KCE-HA。用C-KCE-HA免疫的鸭子诱导了针对H5的交叉反应抗体和T细胞反应。此外,经C-KCE-HA免疫的鸭子对异源HPAIV H5N1和DEV临床症状,死亡和原发性病毒复制提供了快速而持久的保护。总之,我们的BAC-C-KCE是开发多价减毒活疫苗的有前途的平台。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号